NextPharma Management Changes
London – 15 September 2005
NextPharma the leading European provider of drug development and manufacturing outsourcing and distribution services to the pharmaceutical industry has made the following recent changes to its global operations management team:
Pierre Bernard -Vice President Operations – France and Belgium will undertake full management responsibility for Laboratories Thissen S.A. This is a strategic move which brings all of the French speaking manufacturing operations under the control of one person and will provide a consistent and consolidated standard of operations across the French speaking market.
In addition to his new role at Thissen, Pierre will continue to have responsibility for the NextPharma plants in Limay near Paris and Biophelia near Tours. Pierre has extensive operations management experience gained over many years with Aventis, SKB, Boehringer Ingelheim and UCB.
Pierre replaces Didier Menu who undertook the role of General Manager of Thissen for two and a half years and will report directly to Herman Osterwald – Executive Vice President Operations.
Bill Wedlake, CEO, NextPharma Technologies, commented on this change as follows:
“The appointment of Pierre Bernard to this significant operations management role is a further step in positioning NextPharma to serve our customers’ increasingly wide ranging and complex requirements for outsourcing services better. We are totally focused on providing the highest quality services with an emphasis on technical solutions and working in partnership with our customers. It is our objective to ensure that NextPharma remains in a position to offer timely, competitive, healthcare outsourcing solutions of the highest quality as the pharma and biotech markets continue to develop”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing biopharma drug development, clinical trials, packaging and manufacturing outsourcing sector. It has eight manufacturing facilities based in Germany, Belgium and France employing over 1,100 people and has a customer base which includes many of the worlds leading pharmaceutical companies. NextPharma’s principle shareholder is Credit Suisse First Boston Private Equity.
Contact:
Bill Wedlake
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 121
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.